The global bipolar disorder therapeutics market will account for US$ 5.9 Bn in 2022, and is anticipated to reach a valuation of US$ 6.8 Bn by the end of 2026. Consumption of bipolar disorder medications in China is expected to account for a revenue of approximately US$ 514 Mn by the end of 2026.
Increasing prevalence of bipolar disorders and rising awareness regarding mental health are major trends that will driving demand for bipolar disorder therapeutics over the years to come.
Want A Detailed Understanding of Market Functioning? Request for a Sample Here – https://www.factmr.com/connectus/sample?flag=S&rep_id=7280
Bipolar Disorder Therapeutics Market – Scope of Report
A recent study by Fact.MR on the global bipolar disorder therapeutics market offers a 4-year forecast for 2022 to 2026. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with the development of bipolar disorder therapeutic devices.
The study also provides the dynamics that are responsible for influencing the future status of the market over the forecast period. A detailed assessment of value chain analysis, business execution, cost structure analysis, and supply chain analysis across regional markets has been covered in the report.
A list of prominent companies manufacturing bipolar disorder therapeutic drugs, along with their product portfolios, key strategies, and SWOT analysis, enhances the reliability of this comprehensive research study.
Key Segments Covered in Bipolar Disorder Therapeutics Industry Research
Bipolar Disorder Therapeutics Market by Type:
- Antipsychotics Drugs
- Mood Stabilizers
- Antidepressant Drugs
- Anti-anxiety Drugs
Bipolar Disorder Therapeutics Market by Region:
- North America
- Latin America
- East Asia
- South Asia & Oceania
Request Methodology & Get a Glimpse of Our Expertise – https://www.factmr.com/connectus/sample?flag=AE&rep_id=7280
Bipolar disorder treatment providers are investing in the research and development of novel therapeutics to expand their market presence across various regions. Bipolar disorder drug manufacturers are also pushing their offerings to get approvals from regulatory authorities.
In April 2022, Intra-Cellular Therapies, a leading biopharmaceutical organization known for its therapeutics, announced that it had obtained approval for the new dosage strength of CAPLYTA. This drug has proved its efficiency in the treatment of bipolar disorders and will now be available in strengths of 10.5 mg and 21 mg capsules.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Astellas Pharma Inc.
- Allergan plc.
- Johnson & Johnson
- GlaxoSmithKline plc.
- AbbVie Inc.
- Pfizer Inc.
- Novartis International AG.
- Gedeon Richter Plc
- Lundbeck A/S
- Janssen Pharmaceutica N.V.
- Otsuka America Pharmaceutical Inc.
- Sumitomo Dainippon Pharma Co. Ltd.
- Validus Pharmaceuticals LLC